Naveen Pemmaraju, MD
Tagraxofusp (SL-401; Elzonris) led to a 90% overall response rate (ORR) as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to prospective results of a nonrandomized phase II trial that were published in the New England Journal of Medicine
Tagraxofusp is also being investigated in clinical trials for chronic myelomonocytic leukemia and myelofibrosis.
- Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Eng J Med. 2019;380:1628-1637. doi: 10.1056/NEJMoa1815105.
- Study of Tagraxofusp Reports 90 Percent Response Rate for Deadly Blood Cancer with no Prior Available Therapies. The University of Texas MD Anderson Cancer Center. Published April 25, 2019. https://bit.ly/2L2Nv7u. Accessed April 25, 2019.
- Pemmaraju N, Lane AA, Sweet KL, et al. Results of pivotal phase 2 clinical trial of tagraxofusp (SL-401) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In: Proceedings from the 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 765.
... to read the full story